Bod Science Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jo Patterson

İcra Kurulu Başkanı

AU$524.5k

Toplam tazminat

CEO maaş yüzdesi	71.1%
CEO görev süresi	6.5yrs
CEO sahipliği	4.0%
Yönetim ortalama görev süresi	2.5yrs
Yönetim Kurulu ortalama görev süresi	5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jo Patterson'un ücretlendirmesi Bod Science'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2023	AU$524k	AU$373k	-AU$8m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	n/a	n/a	-AU$6m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$520k	AU$341k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$5m
Dec 31 2021	n/a	n/a	-AU$5m
Sep 30 2021	n/a	n/a	-AU$5m
Jun 30 2021	AU$557k	AU$331k	-AU$4m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$5m
Sep 30 2020	n/a	n/a	-AU$5m
Jun 30 2020	AU$421k	AU$315k	-AU$5m
Mar 31 2020	n/a	n/a	-AU$6m
Dec 31 2019	n/a	n/a	-AU$6m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$339k	AU$300k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$6m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$4m
Jun 30 2018	AU$294k	AU$250k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$3m
Dec 31 2017	n/a	n/a	-AU$3m
Sep 30 2017	n/a	n/a	-AU$3m
Jun 30 2017	AU$344k	AU$250k	-AU$3m

Tazminat ve Piyasa: Jo 'ın toplam tazminatı ($USD 343.82K ) Australian pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 298.27K ).

Tazminat ve Kazançlar: Jo şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jo Patterson

6.5yrs

Görev süresi

AU$524,465

Tazminat

Ms. Joanne Patterson, also known as Jo, MBus. (Marketing), serves as Chief Executive Officer of Bod Science Limited (formerly known as Bod Australia Limited). Ms. Patterson founded Bod Australia in 2014.M...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joanne Patterson	CEO, Executive Director & Member of Medical Advisory Board	no data	AU$524.47k	4.05% A$ 172.2k
Adrian Sturrock	Chief Financial Officer	2.5yrs	AU$414.34k	0.11% A$ 4.8k
Craig Weller	CTO & Member of Medical Advisory Board	no data	AU$432.81k	2.74% A$ 116.5k
Adele Hosseini	Chief Scientific Officer & Member of Medical Advisory Board	no data	Veri yok	Veri yok
Alan Dworkin	Advisor	2.5yrs	Veri yok	Veri yok
Carlie Hodges	Company Secretary	1.1yrs	Veri yok	Veri yok

2.5yrs

Ortalama Görev Süresi

Deneyimli Yönetim: BOD 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joanne Patterson	CEO, Executive Director & Member of Medical Advisory Board	6.5yrs	AU$524.47k	4.05% A$ 172.2k
Craig Weller	CTO & Member of Medical Advisory Board	6.5yrs	AU$432.81k	2.74% A$ 116.5k
Adele Hosseini	Chief Scientific Officer & Member of Medical Advisory Board	6.5yrs	Veri yok	Veri yok
David Baker	Non-Executive Chairman	1.8yrs	AU$89.37k	3.59% A$ 153.0k
Ian Olver	Member of Medical Advisory Board	3.2yrs	Veri yok	Veri yok
George Livery	Non-Executive Director	5.4yrs	AU$66.19k	0.22% A$ 9.5k
Stella Valenzuela	Member of Medical Advisory Board	6.5yrs	Veri yok	Veri yok
Nick Burgess	Member of Medical Advisory Board	6.5yrs	Veri yok	Veri yok
Akash Bedi	Non-Executive Director	4.6yrs	AU$66.19k	Veri yok
Iain McGregor	Member of Medical Advisory Board	3.2yrs	Veri yok	Veri yok
Arman Sabet	Member of Medical Advisory Board	3.2yrs	Veri yok	Veri yok
Andrew McLachlan	Member of Medical Advisory Board	3.2yrs	Veri yok	Veri yok

5.0yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BOD 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5 yıldır).

Bod Science Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

No independent directors

Bod Science Limited, Annual General Meeting, Nov 27, 2023

No independent directors

No independent directors

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Recent updates

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

Bod Science Limited has filed a Follow-on Equity Offering in the amount of AUD 2.05 million.

Bod Science Limited announced that it expects to receive AUD 2.05 million in funding

No independent directors

Bod Science Limited has completed a Follow-on Equity Offering in the amount of AUD 1.93008 million.

Bod Science Limited, Annual General Meeting, Nov 27, 2023

Full year 2023 earnings released: AU$0.056 loss per share (vs AU$0.051 loss in FY 2022)

New major risk - Negative shareholders equity

New minor risk - Financial data availability

New major risk - Shareholder dilution

Bod Australia Limited (ASX:BOD) completed the acquisition of Aqua Phase Ltd.

No independent directors

No independent directors

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.02 loss in 1H 2022)

Bod Science Limited Announces Company Secretary Changes

Less than half of directors are independent

Bod Australia Limited Provides Statistical Summary from Its Phase 1 Cannabidiol (CBD) Pharmacokinetic (PK) Study

Bod Australia Limited Announces Resignation of Hanno Cappon as Non-Executive Director

Less than half of directors are independent

Bod Australia Limited, Annual General Meeting, Nov 28, 2022

Less than half of directors are independent

Less than half of directors are independent

Bod Australia Limited to Launch a New Medicinal Cannabis Product to the Australian Market in July

Less than half of directors are independent

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Completes A Proof of Concept Study into the Safety and Efficacy of A Cannabigerol (CBG) Dominant Cannabis Extract Which Has Shown Very Promising Results

Bod Australia Limited Announces Board Changes

Bod Australia Limited Advises That It Has Successfully Enrolled First Patients for Its Australian-Based Planned Phase Iib Clinical Trial

Less than half of directors are independent

Bod Australia Limited Announces First Patients Enrolled for Long-Covid Study Investigating the Efficacy of CBD- Dominant Medicinal Cannabis

Bod Australia Announces Board Changes

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new and inexperienced directors

Bod Australia Limited's Novel Food Application Accepted by UK Food Service Agency

High number of new and inexperienced directors

Bod Australia Limited Announces Ethics Approval Received for Schedule 3 Clinical Trial

Bod Australia Limited Announces Secures Clinical Trial Authorisation from the United Kingdom's Medicines & Healthcare Products Regulatory Agency

High number of new and inexperienced directors

Bod Australia Limited Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings released: AU$0.043 loss per share (vs AU$0.054 loss in FY 2020)

Bod Australia Limited Launches New CBD -Based Products

Bod Australia Limited Provides Update on New Medicinal Cannabis Product Launch

Chief Financial Officer has left the company

New 90-day low: AU$0.41

Bod Australia Limited Announces the Resignation of Charles Altshuler as Chief Financial Officer, Effective 31 March 2021

New 90-day low: AU$0.42

Bod Australia Limited announced that it expects to receive AUD 8 million in funding

Bod Australia Limited Receives AUD 200,000 Binding Purchase Order from Exclusive Global Partner

New 90-day high: AU$0.58

Bod Australia Limited Announces Strong Growth in Medicinal Cannabis Sales Continues

Bod Australia Limited Launches CBD Products in the Netherlands

Bod Australia Limited Undertakes a Phase I Trial of the Safety Tolerability and Pharmacokinetics of Cannabidiol, Administered in Healthy Volunteers Across Multiple Formulations

New 90-day high: AU$0.51

New 90-day high: AU$0.40

New 90-day high - AU$0.32

Full year earnings released - AU$0.054 loss per share

New 90-day low - AU$0.26

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş